Mr. Andrew Kay Mr. Andrew Kay is a Senior Advisor and brings more than 30 years of commercial and leadership experience in the pharmaceutical sector, latest as CEO of Algeta ASA up to the acquisition by Bayer AG. Previous assignments include Executive Director, Commercial, at Renovo, Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and several other senior positions in Europe and the USA with AstraZeneca, Eli Lilly, Sandoz and Boots.
Prof. Bengt Samuelsson Prof. Samuelsson is a Senior Advisor and Professor of Physiological Chemistry and former president of the Karolinska Institute. His research over the years has focused on prostaglandins and leukotrienes. For his work he was awarded the Nobel Prize in Physiology or Medicine in 1982. Prof. Samuelsson is member of the Royal Swedish Academy of Sciences and is Foreign Associate of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, the Institute of Medicine, the Royal Society, London and the French Academy of Science, Paris. He was Chairman of the Nobel Foundation 1993-2005.
Mr. Frank Caufield Mr. Caufield is a Senior Advisor and co-founder of Kleiner Perkins Caufield & Byers (KPCB). Founded in 1972, KPCB is one of the largest and most prominent venture capital firms in the U.S. Mr. Caufield has served on the boards of e.g. Quantum Corporation, Caremark Inc., AOL Inc., Megabios, Verifone Inc., Wyse Technology, Quickturn Corporation and Time Warner. Prior to the formation of KPCB, Mr. Caufield was a General Partner and Manager of Oak Grove Ventures. He is past president of both the Western Association of Venture Capitalists and the National Venture Capital Association.
Dr. Hugh Rienhoff Dr. Rienhoff is a Special Advisor and an entrepreneur and founder of several biotech companies, including Ferrokin BioSciences. He presently serves as CEO of Imago BioSciences, Inc. Dr. Rienhoff has more than 20 years of experience as a venture investor and entrepreneur in the life science sector. He has been working as a partner at New Enterprise Associates and as a director of Abingworth Management Ltd, running their US operation. Dr. Rienhoff is an Adjunct Scientist at the Children’s Hospital Oakland Research Institute. He received his M.D. from the Johns Hopkins University School of Medicine and his B.A. from Williams College.
Mr. Göran Lerenius Mr. Lerenius is a Senior Advisor and a lawyer with a broad and almost 30 year experience in the pharmaceutical industry. Mr. Lerenius served as General Counsel for Astra AB and AstraZeneca Plc between 1984 and 2008 and was company Secretary for Astra AB for 11 years. He has also been responsible for AstraZeneca’s global Intellectual Property Litigation team.
Prof. Kjell Strandberg Prof. Strandberg is a Senior Advisor and Professor in pharmacotherapeutics and the former Director General of the Swedish Medical Products Agency, as well as the former Chairman of NDA Advisory Board, the leading European ex-regulator consultancy group. He is a Medical Doctor and a Member of the Swedish Royal Academy of Engineering Science.
Mr. Ludvik Sandnes Ludvik Sandnes has collected more than 40 years of experience from international corporate finance, asset management and investment banking, inter alia as CEO of UNI Storebrand Asset Management, Dep. CEO of Christiania Bank (now Nordea Norway), Managing Partner of PwC Financial Advisors and of BDO Noraudit, Executive Director of the Royal Bank of Scotland and Investment Director of Norfund. He is chairman of the board of Nordic Nanovector and board member of Oslo Cancer Cluster and other life science companies.
Mr. Louis C Gerken III Mr. Gerken is a Senior Advisor and founder of Gerken Capital Associates (GCA). GCA is an alternative asset fund management firm, with particular focus on the emerging markets. Prior to forming GCA, Mr. Gerken was a Managing Director and Group Head of Prudential Securities Technology Investment Banking Division. Earlier, he was a General Partner to Prudential Securities’ four venture capital funds. Prior thereto he was associated with Montgomery Securities’ Venture Capital Funds, and Wells Fargo Capital Markets.
Prof. Mathias Uhlén Prof. Uhlén is a Senior Advisor and professor in Microbiology at the Royal Institute of Technology, Stockholm. Prof. Uhlén is a Member of the Royal Swedish Academy of Science, the Royal Swedish Academy of Engineering Science, the National Academy of Engineering (USA), the European Molecular Biology Organization (EMBO), steering board member of the Science for Life Laboratory, and member of the Council of the Human Proteome Organisation (HUPO). He has published more than 500 original articles and has also been supervisor and co-supervisor to marathon 100 doctoral theses. He has received numerous awards, including the Svedberg prize in 1992, the Göran Gustavsson prize in 1993, the gold medal of the Royal Swedish Academy of Engineering Sciences in 2004, and The Most Noble Order of the Seraphim – the Order of His Majesty the King in 2004 and the Akzo Nobel Award in 2005. Prof. Uhlén holds a PhD in Technology from the Royal Institute of Technology, Stockholm.
Mr. Per-Olof Mårtensson Mr. Mårtensson is a Senior Advisor and has extensive experience from the pharmaceutical industry in both operational and board positions. Previous positions include COO of Pharmacia AB and Astra AB, as well as CEO of Karo Bio AB and board memberships at Gambro AB, AB Elekta, Nobel Biocare AB, Pharmacia AB and Skandigen AB.
Dr. Ørn Stuge Mr. Stuge is a Senior Advisor and has a broad based experience from senior positions with international life science groups, most recently as member of Medtronic’s Executive team; President of Cardiac Surgery and President of EMEA, Canada & Emerging Markets. Prior to working for Medtronic, Mr. Stuge held positions of Regional Director and General Manager in the Netherlands and the Nordic countries for Abbott Laboratories. Mr. Stuge is a Medical Doctor and holds an MBA from IMD in Lausanne.
Mr. Thomas Halvorsen Mr. Halvorsen is a Senior Advisor and was the CEO of the Fourth Swedish National Pension Fund between 1992 and 2006 and its Chief Investment Officer between 1983 and 1992. The pension fund was one of the early leading Swedish investors in venture capital. Mr. Halvorsen currently acts as an independent financial advisor mainly within private equity and for private companies. He has also previously been a board member of several public companies including AB Electrolux, Sydkraft AB, JM AB, Beijer Alma AB as well as in many small caps.
Mr. Hans Schikan Mr. Hans Schikan is a Senior Advisor. Mr. Schikan brings more than 25 years of development, commercial and leadership experience in the (bio)pharmaceutical sector, latest as CEO of Prosensa in The Netherlands, a company focusing on rare diseases, with a lead program in Duchenne Muscular Dystrophy. During Mr. Schikan’s leadership, Prosensa was listed on NASDAQ in a successful IPO in June 2013. The company was acquired by BioMarin early 2015 for up to USD 840 million. Mr. Schikan’s previous assignments include Vice President, Marketing and Strategy Development for the rare disease portfolio of Genzyme (acquired by Sanofi) and several senior commercial roles in Organon (acquired by Schering Plough). He is currently on the board of a number of biotechnology companies in The Netherlands, Belgium, Sweden and Switzerland. He is also member of the core team of the Dutch Top Sector for Life Sciences and Health.